ARCH Venture Management, LLC - DENALI THERAPEUTICS INC ownership

DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 186 filers reported holding DENALI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.

Quarter-by-quarter ownership
ARCH Venture Management, LLC ownership history of DENALI THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$14,312,042
-30.1%
693,7490.0%9.30%
-26.5%
Q2 2023$20,472,533
-65.4%
693,749
-73.0%
12.64%
-55.7%
Q1 2023$59,183,977
-42.0%
2,568,749
-30.0%
28.57%
+9.3%
Q4 2022$102,027,910
-9.4%
3,668,7490.0%26.13%
+79.0%
Q3 2022$112,594,000
-26.0%
3,668,749
-29.0%
14.60%
-21.3%
Q2 2022$152,116,0005,168,74918.54%
Other shareholders
DENALI THERAPEUTICS INC shareholders Q2 2022
NameSharesValueWeighting ↓
Crestline Management, LP 7,705,039$343,645,00025.68%
Casdin Capital, LLC 1,500,000$66,900,0001.89%
Flagship Pioneering Inc. 2,619,968$116,851,0001.81%
SECTORAL ASSET MANAGEMENT INC 189,600$8,456,0001.27%
Integral Health Asset Management, LLC 100,000$4,460,0001.23%
Temasek Holdings (Private) Ltd 5,369,487$239,479,0000.86%
Goldstream Capital Management Ltd 78,418$3,497,0000.86%
Yiheng Capital Management, L.P. 335,184$14,949,0000.76%
GILDER GAGNON HOWE & CO LLC 2,900,114$129,345,0000.74%
Artal Group S.A. 600,000$26,760,0000.73%
View complete list of DENALI THERAPEUTICS INC shareholders